The Impact of Durvalumab on Lung Cancer Patients with KRAS Mutations
Lung cancer is a complex disease. It is not one-size-fits-all. Stage III non-small cell lung cancer (NSCLC) is a prime example. It is a mixed bag of different subgroups. Some respond well to treatment. Others do not. This is why identifying these subgroups is so important. It helps doctors ta